RSS-Feed abonnieren
DOI: 10.1055/s-0041-1725197
Real-Life Management of Central and Branch Retinal Vein Occlusion: A Seven-Year Follow-Up Study
Abstract
Retinal vein occlusion is the second most common retinal vascular pathology after diabetic retinopathy and a major cause of vision impairment. Nowadays, both central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) can be well-managed by intravitreal treatments. However, considering the long-life expectance of the patients, few data are present in the literature about the very long-term outcome of CRVO and BRVO. The present study was an interventional, retrospective analysis of the morphological and functional long-term outcome of CRVO and BRVO patients, followed in an Italian referral center. We collected data from 313 eyes (178 CRVO eyes and 135 BRVO eyes). Mean follow-up was 45 ± 25 months (range 12–84 months). Both CRVO and BRVO eyes experience a significant visual acuity improvement secondary to anti-vascular endothelial growth factor/dexamethasone treatments (from 0.57 ± 0.25 to 0.41 ± 0.24 LogMAR in CRVO and from 0.53 ± 0.42 to 0.30 ± 0.41 LogMAR in BRVO, respectively) (p < 0.01). Also, central macular thickness (CMT) resulted significant recovery at the end of the follow-up (from 585.54 ± 131.43 to 447.88 ± 245.07 μm in CRVO and from 585.54 ± 131.43 to 447.88 ± 245.07 μm in BRVO, respectively) (p < 0.01). CRVO eyes received a mean of 10.70 ± 4.76 intravitreal treatments, whereas BRVO underwent 9.80 ± 5.39 injections over the entire 7-year follow-up. Our analyses highlighted different time points indicating the best obtainable improvement. This was the first year for CRVO (12-month follow-up) and the second year for BRVO (24-month follow-up). After these two time points, both visual acuity and CMT resulted stable up to the end of the follow-up. Ischemia was associated with significantly worse outcome.
Keywords
central retinal vein occlusion - branch retinal vein occlusion - optical coherence tomography - real-life study - intravitreal injectionPublikationsverlauf
Eingereicht: 14. Dezember 2020
Angenommen: 23. Januar 2021
Artikel online veröffentlicht:
11. März 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117 (04) 429-441
- 2 Rogers S, McIntosh RL, Cheung N. et al; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117 (02) 313-319
- 3 Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res 2014; 41: 1-25
- 4 Noma H, Funatsu H, Sakata K. et al. Macular microcirculation and macular oedema in branch retinal vein occlusion. Br J Ophthalmol 2009; 93 (05) 630-633
- 5 Noma H, Funatsu H, Mimura T, Eguchi S, Hori S. Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. Am J Ophthalmol 2011; 152 (04) 669-677
- 6 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118 (10) 2041-2049
- 7 Kinge B, Stordahl PB, Forsaa V. et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150 (03) 310-314
- 8 Haller JA, Bandello F, Belfort Jr R. et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117 (06) 1134-1146
- 9 Haller JA, Bandello F, Belfort Jr R. et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118 (12) 2453-2460
- 10 Heier JS, Campochiaro PA, Yau L. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119 (04) 802-809
- 11 Campochiaro PA, Sophie R, Pearlman J. et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014; 121 (01) 209-219
- 12 Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P. Ranibizumab for retinal vein occlusion: predictive factors and long-term outcomes in real-life data. Retina 2018; 38 (03) 559-568
- 13 Spooner K, Fraser-Bell S, Hong T, Chang AA. Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. BMJ Open Ophthalmol 2019; 29 (04) e000249
- 14 Maggio E, Mete M, Maraone G, Attanasio M, Guerriero M, Pertile G. Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes. J Ophthalmol 2020; 2020: 7817542
- 15 Brown DM, Campochiaro PA, Singh RP. et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117 (06) 1124-1133
- 16 Boyer D, Heier J, Brown DM. et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012; 119 (05) 1024-1032
- 17 Brown DM, Heier JS, Clark WL. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155 (03) 429-437
- 18 Heier JS, Clark WL, Boyer DS. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121 (07) 1414-1420
- 19 Holz FG, Roider J, Ogura Y. et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013; 97 (03) 278-284
- 20 Korobelnik JF, Holz FG, Roider J. et al; GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014; 121 (01) 202-208
- 21 Ogura Y, Roider J, Korobelnik JF. et al; GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 2014; 158 (05) 1032-1038
- 22 Battaglia Parodi M, Iacono P, Sacconi R, Parravano M, Varano M, Bandello F. Dexamethasone implant for macular edema secondary to central retinal vein occlusion in patients younger than 50 years. Retina 2015; 35 (07) 1381-1386
- 23 Larsen M, Waldstein SM, Priglinger S. et al; CRYSTAL Study Group. Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the CRYSTAL study. Ophthalmol Retina 2018; 2 (02) 134-142
- 24 Brown DM, Campochiaro PA, Bhisitkul RB. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118 (08) 1594-1602
- 25 Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL. RAVE Study Group. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the Rubeosis anti-VEGF (RAVE) trial. Retina 2014; 34 (09) 1728-1735
- 26 Rezar S, Eibenberger K, Bühl W, Georgopoulos M, Schmidt-Erfurth U, Sacu S. Macula Study Group Vienna. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol 2015; 93 (08) 719-725
- 27 Clark WL, Boyer DS, Heier JS. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123 (02) 330-336
- 28 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER study group. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016; 123 (06) 1332-1344
- 29 Tadayoni R, Waldstein SM, Boscia F. et al; BRIGHTER Study Group. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 2017; 124 (12) 1778-1787
- 30 Battaglia Parodi M, Romano F, Arrigo A. et al. Real-life anti-vascular endothelial growth factor treatment for age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital. Eur J Ophthalmol 2020; 30 (06) 1461-1466
- 31 Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res 2017; 58 (04) 203-208
- 32 Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol 2018; 63 (06) 816-850